Tenax Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TENX Nasdaq 2830 www.tenaxthera.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tenax Therapeutics, Inc.

Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 12th, 2026 5:00 am
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 8th, 2026 2:05 pm
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer - May 4th, 2026 5:00 am
Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth - Apr 22nd, 2026 7:20 am
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer - Apr 22nd, 2026 5:00 am
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls - Mar 17th, 2026 7:33 am
Tenax Therapeutics: Q4 Earnings Snapshot - Mar 10th, 2026 5:24 am
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Mar 10th, 2026 5:00 am
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference - Mar 3rd, 2026 5:00 am
Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference - Feb 15th, 2026 11:03 am
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 - Feb 4th, 2026 5:00 am
Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick - Jan 8th, 2026 12:00 pm
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment - Dec 17th, 2025 7:16 am
Tenax Therapeutics to Participate in Upcoming Investor Conferences - Nov 25th, 2025 5:00 am
Tenax Therapeutics: Q3 Earnings Snapshot - Nov 12th, 2025 2:17 pm
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 12th, 2025 2:05 pm
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF - Nov 6th, 2025 5:00 am
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - Nov 3rd, 2025 5:00 am
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF - Sep 16th, 2025 5:00 am
Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025 - Aug 28th, 2025 5:00 am